

Pyoderma Gangrenosum (PG) - Pipeline Insight, 2019

<https://marketpublishers.com/r/P754F06639BEN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: P754F06639BEN

Abstracts

This report can be delivered to the clients within 24 Hours

"Pyoderma Gangrenosum (PG) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pyoderma Gangrenosum pipeline landscape is provided which includes the disease overview and Pyoderma Gangrenosum treatment guidelines. The assessment part of the report embraces, in depth Pyoderma Gangrenosum commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pyoderma Gangrenosum collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Pyoderma Gangrenosum Understanding

Pyoderma gangrenosum (PG) is an inflammatory skin disorder that is characterized by small, red bumps or blisters (papules or nodules) that eventually erode to form swollen open sores (ulcerations). The size and depth of the ulcerations vary greatly, and they are often extremely painful. In approximately 50 percent of cases, PG occurs secondary to another disorder such as inflammatory bowel disease. The exact cause of PG is unknown (idiopathic). Pyoderma gangrenosum usually starts with a small, red bump on your skin, which may resemble a spider bite. Within days, this bump can develop into a large, painful open sore. These small growths eventually develop into swollen, open sores (ulcerations) with a well-defined blue or violet-colored border. The size and depth of ulcerations vary. The exact cause of pyoderma gangrenosum is unknown (idiopathic) although it is suspected to be an autoimmune disease.

Pyoderma Gangrenosum Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Pyoderma Gangrenosum targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Pyoderma Gangrenosum pipeline report covers 7+ companies. Some of the key players include InflaRx (IFX 1), Eli Lilly (Ixezumab) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Pyoderma Gangrenosum Analytical Perspective by DelveInsight

In-depth Pyoderma Gangrenosum Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Pyoderma Gangrenosum Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

The Pyoderma Gangrenosum report provides an overview of therapeutic pipeline activity for Pyoderma Gangrenosum across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Pyoderma Gangrenosum therapeutic

products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Pyoderma Gangrenosum Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Pyoderma Gangrenosum

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Pyoderma Gangrenosum to formulate effective R&D strategies

Assess challenges and opportunities that influence Pyoderma Gangrenosum R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each project along with key milestones

Devise Pyoderma Gangrenosum in licensing and out licensing strategies by identifying prospective partners with progressing projects for Pyoderma Gangrenosum to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Contents

1. REPORT INTRODUCTION

2. PYODERMA GANGRENOSUM

- 2.1. Pyoderma Gangrenosum Disease Overview
- 2.2. Pyoderma Gangrenosum History
- 2.3. Pyoderma Gangrenosum Symptoms
- 2.4. Pyoderma Gangrenosum Causes
- 2.5. Pyoderma Gangrenosum Pathophysiology
- 2.6. Pyoderma Gangrenosum Diagnosis
 - 2.6.1. Diagnostic Guidelines

3. PYODERMA GANGRENOSUM CURRENT TREATMENT PATTERNS

- 3.1. Treatment Guidelines

4. PYODERMA GANGRENOSUM- DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 4.1. In-depth Commercial Assessment
 - 4.1.1. Pyoderma Gangrenosum companies collaborations, Licensing, Acquisition –Deal Value Trends
 - 4.1.1.1. Assessment Summary
 - 4.1.2. Pyoderma Gangrenosum Collaboration Deals
 - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
 - 4.1.2.2. Pyoderma Gangrenosum Acquisition Analysis
- 4.2. Clinical Assessment of Pipeline Drugs
 - 4.2.1. Assessment by Phase of Development
 - 4.2.2. Assessment by Product Type (Mono / Combination)
 - 4.2.2.1. Assessment by Stage and Product Type
 - 4.2.3. Assessment by Route of Administration
 - 4.2.3.1. Assessment by Stage and Route of Administration
 - 4.2.4. Assessment by Molecule Type
 - 4.2.4.1. Assessment by Stage and Molecule Type
 - 4.2.5. Assessment by MOA
 - 4.2.5.1. Assessment by Stage and MOA

5. PYODERMA GANGRENOSUM PIPELINE THERAPEUTICS

- 5.1. Late Stage Products (Phase-III)
 - 5.1.1. Comparative Analysis
- 5.2. Mid Stage Products (Phase-II)
 - 5.2.1. Comparative Analysis
- 5.3. Early Stage Products (Phase-I)
 - 5.3.1. Comparative Analysis
- 5.4. Pre-clinical and Discovery Stage Products
 - 5.4.1. Comparative Analysis
- 5.5. Inactive Products

6. PYODERMA GANGRENOSUM-PRODUCTS ANALYSIS

- 6.1. Product Profiles
 - 6.1.1. IFX 1- InflaRx
 - 6.1.1.1. Product Description
 - 6.1.1.1.1. Product Overview
 - 6.1.1.1.2. Mechanism of Action
 - 6.1.1.2. Research and Development
 - 6.1.1.2.1. Clinical Studies
 - 6.1.1.2.1.1. Detailed Study Description
 - 6.1.1.2.1.2. Study Results
 - 6.1.1.2.1.3. Clinical Trials: Tabular View
 - 6.1.1.3. Product Development Activities
 - 6.1.1.3.1. Tabulated Product Summary
 - 6.1.1.3.1.1. General Description Table
 - 6.1.2. Ixekizumab- Eli Lilly
 - 6.1.2.1. Product Description
 - 6.1.2.1.1. Product Overview
 - 6.1.2.1.2. Mechanism of Action
 - 6.1.2.2. Research and Development
 - 6.1.2.2.1. Clinical Studies
 - 6.1.2.2.1.1. Detailed Study Description
 - 6.1.2.2.1.2. Study Results
 - 6.1.2.2.1.3. Clinical Trials: Tabular View
 - 6.1.2.3. Product Development Activities
 - 6.1.2.3.1. Tabulated Product Summary
 - 6.1.2.3.1.1. General Description Table
- To be continued in the report.....

7. RECENT TECHNOLOGIES

8. PYODERMA GANGRENOSUM KEY COMPANIES

- 8.1. AbbVie
- 8.2. XBiotech
- 8.3. InflaRx
- 8.4. XOMA
- 8.5. Arena Pharmaceuticals
- 8.6. Eli Lilly
- 8.7. Aclaris Therapeutics

9. PYODERMA GANGRENOSUM KEY PRODUCTS

- 9.1. Adalimumab
- 9.2. Bermekimab
- 9.3. IFX 1
- 9.4. Gevokizumab
- 9.5. Etrasimod
- 9.6. Ixekizumab
- 9.7. ATI 450

10. DORMANT AND DISCONTINUED PRODUCTS

- 10.1. Dormant Products
 - 10.1.1. Reasons for being dormant
- 10.2. Discontinued Products
 - 10.2.1. Reasons for the discontinuation

11. PYODERMA GANGRENOSUM- UNMET NEEDS

12. PYODERMA GANGRENOSUM- FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

- 14.1. Secondary Research

14.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

- Table 1. Pyoderma Gangrenosum Diagnostic Guidelines
- Table 2. Treatment Guidelines
- Table 3. Assessment Summary
- Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5. Pyoderma Gangrenosum Acquisition Analysis
- Table 6. Assessment by Phase of Development
- Table 7. Assessment by Product Type (Mono / Combination)
- Table 8. Assessment by Stage and Product Type
- Table 9. Assessment by Route of Administration
- Table 10. Assessment by Stage and Route of Administration
- Table 11. Assessment by Molecule Type
- Table 12. Assessment by Stage and Molecule Type
- Table 13. Assessment by MOA
- Table 14. Assessment by Stage and MOA
- Table 15. Late Stage Products (Phase-III)
- Table 16. Mid Stage Products (Phase-II)
- Table 17. Early Stage Products (Phase-I)
- Table 18. Pre-clinical and Discovery Stage Products
- Table 19. Inactive Products
- Table 20. Dormant Products
- Table 21. Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1. Disease Overview
- Figure 2. History
- Figure 3. Symptoms
- Figure 4. Causes
- Figure 5. Pathophysiology
- Figure 6. Diagnostic Guidelines
- Figure 7. Treatment Guidelines
- Figure 8. Pyoderma Gangrenosum companies collaborations, Licensing, Acquisition –Deal Value Trends
- Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10. Pyoderma Gangrenosum Acquisition Analysis
- Figure 11. Assessment by Phase of Development
- Figure 12. Assessment by Product Type (Mono / Combination)
- Figure 13. Assessment by Stage and Product Type
- Figure 14. Assessment by Route of Administration
- Figure 15. Assessment by Stage and Route of Administration
- Figure 16. Assessment by Molecule Type
- Figure 17. Assessment by Stage and Molecule Type
- Figure 18. Assessment by MOA
- Figure 19. Assessment by Stage and MOA
- Figure 20. Late Stage Products (Phase-III)
- Figure 21. Mid Stage Products (Phase-II)
- Figure 22. Early Stage Products (Phase-I)
- Figure 23. Pre-clinical and Discovery Stage Products
- Figure 24. Inactive Products
- Figure 25. Dormant Products
- Figure 26. Discontinued Products
- Figure 27. Unmet Needs

KEY COMPANIES

AbbVie
XBiotech
InflaRx
Janssen Biotech

AbbVie

XOMA

Arena Pharmaceuticals

Eli Lilly

Aclaris Therapeutics

I would like to order

Product name: Pyoderma Gangrenosum (PG) - Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/P754F06639BEN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P754F06639BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970